CORT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
CORT 近期報酬表現
4.72%
Corcept therapeutics incorporated
1.96%
同產業平均
0.51%
S&P500
與 CORT 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
AVXL | Anavex life sciences corp. | 2 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
RVNC | Revance therapeutics inc | 5 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
KURA | Kura oncology inc | 2 分 | 5 分 | 4 分 | 3 分 | 1 分 | |
SUPN | Supernus pharmaceuticals inc | 4 分 | 5 分 | 3 分 | 3 分 | 1 分 |
- AVXL Anavex life sciences corp.價值 2 分趨勢 1 分波段 2 分籌碼 2 分股利 1 分查看更多
CORT 公司資訊
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.